retatrutide triple agonist glp-1 gip glucagon phase 2 results hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Eli Lilly's retatrutide shows promising

Stress and poor sleep spike cortisol, fueling cravings for sugary, fatty foods

There is a $4.1 billion facility in the works where significant quantities of Ozempic and Wegovy can be manufactured, which will increase the available supply of these drugs and hopefully bring down the sticker price, but it will be at least 3 or 4 years before these products would be available

Here, we assessed GLP-1R expression by immunohistochemistry in a large collection of 576 patient NENs from 13 sites of origin

In a prospective observational cohort study, Sullivan et al

Novocare follows a similar effort launched last year called LillyDirect, a direct-to-patient effort from Eli Lilly, maker of the GLP-1 drug Zepbound